Everyday Investors Can Now Buy Stock in Pioneering Wearable Medical Robotics Company

Myomo, Inc. has launched a Regulation A+ initial public offering that allows any investor the opportunity to invest in the Company’s vision for expanded mobility for those suffering from neurological disorders and upper-limb paralysis.

Myomo is seeking to become the first company to launch a Regulation A+ IPO and have its stock listed on the New York Stock Exchange MKT (NYSE MKT). TriPoint Global Equities, LLC, working with its online division BANQ® (, will act as the lead managing selling agent and book runner for the offering. Myomo intends to use the proceeds from the offering to fund its sales and marketing expansion, product development, repayment of debt and for working capital and other general corporate purposes.

“We are very excited to share our vision of restoring upper limb mobility to millions of Americans and others worldwide with a broad set of individual investors that now have the opportunity to invest in our Company, alongside accredited investors and institutions, to acquire shares at the initial offering price,” said Paul R. Gudonis, CEO of Myomo. “While a traditional public offering generally would allow only accredited investors to invest at this stage, we are taking advantage of new SEC regulations to level the playing field for all investors to participate concurrently in our IPO."

“I am thrilled that Myomo is attempting to become the first company to ever bring a Regulation A+ offering to the NYSE MKT,” said Mark Elenowitz, CEO of TriPoint. “It has been 84 years since the Securities Act of 1933 was enacted. Now, thanks to Title IV of the Jumpstart Our Business Startups (JOBS) Act, Myomo has the chance to take us into exciting new territory where Main Street meets Wall Street.”

The Opportunity to Invest in Myomo

Myomo has previously raised more than $20 million from management, individual investors with healthcare and high-technology experience, as well as Mountain Group Capital. The company seeks to raise up to $15 million in its IPO under Regulation A+ and then, in succession and subject to NYSE requirements, be listed on the NYSE MKT as “MYO.” Individuals interested in learning more about the Myomo Regulation A+ investment opportunity can visit

Investor Relations

For Myomo:

For PCG Advisory:

Vivian Cervantes

(212) 554-5482

Legal Disclaimer
Myomo Inc.’s offering statement for its initial public offering under Regulation A has been qualified by the Securities and Exchange Commission. The securities offered by Myomo Inc. are highly speculative. Investing in shares of Myomo Inc. involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. To obtain a copy of the Offering Circular, go to or click here to download directly.
Forward-Looking Statements
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as “expected,” “anticipated,” “projected” and “forecasted.” Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

How can we help?

Keep in Touch

Sign up to hear of new developments